344 related articles for article (PubMed ID: 9808338)
1. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R; Gash DM
J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective and neurorestorative properties of GDNF.
Gash DM; Zhang Z; Gerhardt G
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S121-5. PubMed ID: 9749583
[TBL] [Abstract][Full Text] [Related]
3. Functional recovery in parkinsonian monkeys treated with GDNF.
Gash DM; Zhang Z; Ovadia A; Cass WA; Yi A; Simmerman L; Russell D; Martin D; Lapchak PA; Collins F; Hoffer BJ; Gerhardt GA
Nature; 1996 Mar; 380(6571):252-5. PubMed ID: 8637574
[TBL] [Abstract][Full Text] [Related]
4. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
5. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
Costa S; Iravani MM; Pearce RK; Jenner P
Eur J Pharmacol; 2001 Jan; 412(1):45-50. PubMed ID: 11166735
[TBL] [Abstract][Full Text] [Related]
6. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys.
Zhang Z; Miyoshi Y; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1396-401. PubMed ID: 9316852
[TBL] [Abstract][Full Text] [Related]
7. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
8. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
9. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
Kirik D; Rosenblad C; Björklund A
Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
[TBL] [Abstract][Full Text] [Related]
10. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
11. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
13. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
Kearns CM; Gash DM
Brain Res; 1995 Feb; 672(1-2):104-11. PubMed ID: 7749731
[TBL] [Abstract][Full Text] [Related]
14. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
Grondin R; Zhang Z; Yi A; Cass WA; Maswood N; Andersen AH; Elsberry DD; Klein MC; Gerhardt GA; Gash DM
Brain; 2002 Oct; 125(Pt 10):2191-201. PubMed ID: 12244077
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
Kobayashi S; Ogren SO; Hoffer BJ; Olson L
Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
[TBL] [Abstract][Full Text] [Related]
16. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
17. GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution.
Grondin R; Littrell OM; Zhang Z; Ai Y; Huettl P; Pomerleau F; Quintero JE; Andersen AH; Stenslik MJ; Bradley LH; Lemmon J; O'Neill MJ; Gash DM; Gerhardt GA
Neuropharmacology; 2019 Mar; 147():28-36. PubMed ID: 29857941
[TBL] [Abstract][Full Text] [Related]
18. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease.
Lapchak PA; Gash DM; Jiao S; Miller PJ; Hilt D
Exp Neurol; 1997 Mar; 144(1):29-34. PubMed ID: 9126148
[TBL] [Abstract][Full Text] [Related]
19. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.
Nakao N; Yokote H; Nakai K; Itakura T
J Neurosurg; 2000 Apr; 92(4):659-70. PubMed ID: 10761657
[TBL] [Abstract][Full Text] [Related]
20. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys.
Gash DM; Zhang Z; Cass WA; Ovadia A; Simmerman L; Martin D; Russell D; Collins F; Hoffer BJ; Gerhardt GA
J Comp Neurol; 1995 Dec; 363(3):345-58. PubMed ID: 8847404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
